

Prevention of Recurrent Depression With Cognitive Behavioral Therapy

Preliminary Findings

Giovanni A. Fava, MD; Chiara Rafanelli, MD; Silvana Grandi, MD; Sandra Conti, MD; Piera Belluardo, PhD

Background: Cognitive behavioral treatment (CBT) of residual symptoms after successful pharmacotherapy yielded a substantially lower relapse rate than did clinical management in patients with primary major depressive disorders. The aim of this study was to test the effectiveness of this approach in patients with recurrent depression (≥ 3 episodes of depression).

Methods: Forty patients with recurrent major depression who had been successfully treated with antidepressant drugs were randomly assigned to either CBT of residual symptoms (supplemented by lifestyle modification and well-being therapy) or clinical management. In both groups, during the 20-week experiment, antidepressant drug administration was tapered and discontinued. Residual symptoms were measured with a modified version of the Paykel Clinical Interview for Depression. Two-year follow-up was undertaken, during which no antidepressant drugs were used unless a relapse ensued.

Results: The CBT group had a significantly lower level of residual symptoms after discontinuation of drug therapy compared with the clinical management group. At 2-year follow-up, CBT also resulted in a lower relapse rate (25%) than did clinical management (80%). This difference attained statistical significance by survival analysis.

Conclusions: These results challenge the assumption that long-term drug treatment is the only tool to prevent relapse in patients with recurrent depression. Although maintenance pharmacotherapy seems to be necessary in some patients, CBT offers a viable alternative for other patients. Amelioration of residual symptoms may reduce the risk of relapse in depressed patients by affecting the progression of residual symptoms to prodromes of relapse.

Arch Gen Psychiatry. 1998;55:816-820

THE CHRONIC and recurrent nature of major depressive disorders is getting increasing attention.^{1,2} The development of improved maintenance treatment strategies for depressed patients with a history of recurrent episodes has thus become a crucial clinical and research issue.^{3,4} Substantial evidence supports the efficacy of long-term antidepressant medication use in patients with recurrent depression.^{3,4} In particular, Frank et al⁵ conducted a randomized 3-year maintenance trial in 128 patients with recurrent depression who had responded to combined short-term and continuation treatment with imipramine hydrochloride and interpersonal psychotherapy. A 5-cell design was used to determine whether imipramine therapy, placebo, and interpersonal psychotherapy could play a significant role in the prevention of recurrence. Use of imipramine hydrochloride, at an average dosage of 200 mg/d, provided the strongest prophylactic effect, whereas monthly interpersonal psychotherapy displayed a modest protective effect, although the latter was superior to placebo⁵ and was more

pronounced when the psychotherapy was of higher quality.^{6,7} Extension of treatment with imipramine or placebo provided additional evidence for the prophylactic effect of drug treatment.⁸ The clinical consequence of this important investigation is that patients with recurrent depression merit continued antidepressant drug prophylaxis for at least 5 years, although psychological therapies also were useful.^{6,7}

Indeed, in a recent study,⁹ 75 patients with recurrent depression were allocated to 3 groups: short-term and maintenance (2 years) treatment with antidepressant drugs, cognitive behavioral treatment (CBT) in the short-term and maintenance phases, and antidepressant use in the short-term phase and CBT for maintenance. Cognitive therapy displayed a similar prophylactic effect to maintenance medication.⁹

The criterion for recurrent depression (at least 1 previous episode of depression) was different, however, from that endorsed by Frank et al⁵ (≥ 3 episodes of unipolar depression, with the immediately preceding episode being no more than 2½ years before the onset of the present episode). It is difficult to know, thus, whether the cognitive

From the Department of Psychiatry, State University of New York at Buffalo (Dr Fava), and the Affective Disorders Program and Laboratory of Experimental Psychotherapy, Department of Psychology, University of Bologna, Bologna (Drs Fava, Rafanelli, Grandi, and Conti), and the Department of Statistical Sciences, University of Padova, Padova (Dr Belluardo), Italy.

PATIENTS AND METHODS

PATIENTS

Forty-five consecutive outpatients satisfying the criteria described below who had been referred to and treated in the Affective Disorders Program of the University of Bologna School of Medicine, Bologna, Italy, were enrolled in the study. The patients' diagnoses were established by the consensus of a psychiatrist (G.A.F.) and a clinical psychologist (C.R.) independently using the Schedule for Affective Disorders and Schizophrenia.¹³ Patients had to meet the following criteria: (1) a current diagnosis of major depressive disorder according to the *Research Diagnostic Criteria for a Selected Group of Functional Disorders*¹⁴; (2) 3 or more episodes of depression, with the immediately preceding episode being no more than 2½ years before the onset of the present episode⁵; (3) a minimum 10-week remission according to Research Diagnostic Criteria (≤ 2 symptoms present to no more than a mild degree with absence of functional impairment) between the index episode and the immediately preceding episode⁵; (4) a minimum global severity score of 7 for the current episode of depression¹⁵; (5) no history of manic, hypomanic, or cyclothymic features; (6) no history of active drug or alcohol abuse or dependence or of personality disorder according to *DSM-IV* criteria¹⁶; (7) no history of antecedent dysthymia; (8) no active medical illness; and (9) successful response to antidepressant drugs administered by 2 psychiatrists (S.G. and S.C.) according to a standardized protocol.¹⁷ The latter protocol involved the use of tricyclic antidepressant drugs, with gradual increases in dosages. Patients who could not tolerate tricyclic antidepressant drugs were switched to selective serotonin reuptake inhibitors (**Table 1**).

After drug treatment, all patients were assessed by the same psychologist (C.R.) who had evaluated them on intake but who did not take part in the treatment. Only patients rated as "better" or "much better" according to a global scale of improvement¹⁵ and as being in full remission¹⁹ were included in the study. Patients also had to show no

evidence of depressed mood after treatment according to a modified version of the Paykel Clinical Interview for Depression (CID).²⁰ Patients fit the criteria for stage 3 (the residual phase) of unipolar depression according to a staging system developed previously.²¹ Written informed consent was secured from all patients.

All patients were treated for 3 to 5 months with full doses of antidepressant drugs (Table 1), after which the modified version of the CID was administered by the clinical psychologist. This interview covered 19 symptom areas, as described in detail elsewhere.¹⁰ Each item is rated on a 1- to 7-point scale, with 1 indicating absence of symptoms and 7, very incapacitating symptoms. The scale includes a wider range of symptoms (such as irritability and phobic anxiety) compared with other scales and is particularly suitable for assessing subclinical symptoms of affective disorders,²²⁻²⁷ also in view of its capacity to measure small increments or small changes near the normal end of the spectrum.^{10,22} Furthermore, it has been fully and independently validated for Italian populations.^{24-26,28-31}

TREATMENT

After assessment with the CID, the 45 patients were randomly assigned to 1 of 2 treatment groups: (1) pharmacotherapy and CBT or (2) pharmacotherapy and CM. In both groups, treatment consisted of ten 30-minute sessions once every other week. Antidepressant drug use was tapered at the rate of 25 mg of amitriptyline hydrochloride or its equivalent every other week, and then the drugs were withdrawn completely (in the last 2 sessions, all patients were drug free). Discontinuation of antidepressant drug use was not feasible for 5 patients (3 in the CBT group and 2 in the CM group), and they were excluded from the study at that point. The same psychiatrist (G.A.F.) performed all treatments in both groups.

Cognitive behavioral treatment consisted of the following 3 main ingredients: (1) CBT of residual symptoms of major depression.^{10,32} Cognitive therapy was conducted

Continued on next page

approach would be effective also in a patient population characterized by a more severe course of illness.⁵

In earlier studies,^{10,11} an alternative treatment strategy for decreasing the relapse rate of major depression was developed. This strategy is based on the fact that the presence of residual symptoms after completion of drug or psychotherapeutic treatment has been correlated with poor long-term outcome¹ and that some residual symptoms of major depression may progress to prodromal symptoms of relapse.¹² In those studies,^{10,11} 40 patients with primary major depressive disorder who had been successfully treated with antidepressant drugs were randomly assigned to either CBT of residual symptoms or standard clinical management (CM).¹⁰ In both types of treatment, antidepressant drugs were gradually tapered and discontinued. The CBT group had a significantly lower level of residual symptoms after discontinuation of drug therapy than the CM group. Cognitive behavioral treatment also resulted in a significantly lower rate of relapse (35%) at 4-year follow-up than did CM (70%).¹¹

The purpose of this study was to apply this therapeutic approach to a sample of depressed patients, whose clinical

features matched those in the study by Frank et al⁵ on recurrent depression, and to compare the effectiveness of this approach with that of standard CM without the use of CBT. In both types of treatment, antidepressant drug use was gradually tapered and discontinued. In view of the considerable clinical challenge, CBT of residual symptoms was supplemented by relapse preventive strategies.

RESULTS

Forty patients (20 in each group) completed the 20-week experiment. There were no significant differences between the groups in any of the variables listed in Table 1 or in severity of residual symptoms as measured by the CID (**Table 2**). Comorbidity was considered only if it persisted after treatment of acute depression and satisfied Research Diagnostic Criteria.¹⁴ A few patients were taking benzodiazepines at low doses and continued to do so throughout the study.

Cognitive behavioral treatment induced significant improvement in residual symptoms, whereas there were no significant changes in the CM group. When the

as described by Beck et al.^{33,34} The psychiatrist (G.A.F.), an experienced therapist, used strategies and techniques designed to help depressed patients correct their distorted views and maladaptive beliefs, particularly regarding symptoms concerned with anxiety and irritability, which constitute the bulk of residual symptoms in patients with depression.¹⁰ Whenever appropriate, as in the case of residual symptoms related to anxiety, exposure strategies were planned with the patient,³⁵ eg, in the case of exposure to phobic external cues in agoraphobia or social phobia.²⁵ (2) Lifestyle modification. Patients were instructed that depression is merely the consequence of a maladaptive lifestyle, which does not take life stress, interpersonal friction, excessive work, and inadequate rest into proper account. Antidepressant drugs restore normal mood, but relapse may ensue if inappropriate lifestyle behaviors are continued after drug withdrawal. Patients were encouraged to modify their schedules, arrangements, etc, accordingly. The strategies used technically derived from lifestyle modification approaches that were effective in clinical cardiological studies.³⁶ (3) Well-being therapy. In the last 2 or 3 sessions, a psychotherapeutic strategy for enhancing well-being³⁷ was used. The technique is aimed at changing beliefs and attitudes detrimental to well-being, stimulating awareness of personal growth and recovery from affective illness, and reinforcing behavior promoting well-being.³⁷ It is based on Ryff and Singer's³⁸ conceptual model of well-being as the result of self-acceptance, positive relations with others, autonomy, environmental mastery, purpose in life, and personal growth.

Clinical management consisted of monitoring medication tapering, reviewing the patient's clinical status, and providing the patient with support and advice if necessary. In CM, specific interventions such as exposure strategies, diary work, and cognitive restructuring were prescribed. The patient was encouraged to share the main events that took place in the previous 2 weeks. Treatment integrity was checked by submitting 8 randomly selected taped sessions (4 involving CBT and 4 involving CM) to 2 independent assessors, who correctly identified all sessions.

The 40 patients were reassessed with the CID, after treatment and while drug free, by the same clinical psychologist (C.R.) who had performed the previous evaluations and who was unaware of treatment assignment. The patients were then assessed 3, 6, 9, 12, 15, 18, 21, and 24 months after treatment. They were instructed to call immediately if any new symptoms appeared and were guaranteed a renewed course of antidepressant drug therapy only in the event of relapse. Follow-up evaluation consisted of a brief update of clinical and medical status, including any treatment contacts or use of medications. Relapse was defined as the occurrence of a Research Diagnostic Criteria-defined episode of major depression. During follow-up (unless a relapse occurred), no patient received additional antidepressant drug treatment or psychotherapeutic intervention.

STATISTICAL METHODS

The 2-tailed *t* test and the χ^2 test were used to compare the 2 groups and to evaluate changes in residual symptoms within each of the treatment groups. Analysis of covariance was used for comparing the means of the residual symptoms scores, with adjustment for any difference in the first assessment. Survival analysis³⁹ was used for time until relapse into major depression. Six factors were investigated as possible predictors of outcome: assignment to CBT or CM, age, sex, duration of the depressive episode, number of previous depressive episodes, and number of residual symptoms regardless of—and before—treatment assignment. The Kaplan-Meier method was used for estimating survival curves. Because relapse was the event of interest, survival refers to relapse-free status. Each factor was dichotomized with a cutoff point around the median for measurement-type factors. The log-rank test and the Cox proportional hazards regression model were used to compare any 2 survival distributions for each of the 6 factors considered. For all tests performed, the significance level was .05, 2-tailed. Results are expressed as mean (SD).

residual symptoms at the second assessment (after CBT or CM) of the groups were compared, with their initial measurements as covariates, a significant effect of CBT was found ($F_{1,37} = 31.54, P < .001$).

During the 2-year follow-up, 5 patients (25%) in the CBT group and 16 patients (80%) in the CM group relapsed. The mean survival times were 91.8 (22.4) weeks for the CBT group and 62.2 (26.6) weeks for the CM group ($t_{38} = 3.81, P < .001$). Of the 6 variables selected for survival analysis, only treatment assignment (**Figure**) attained statistical significance (log-rank test, $\chi^2_1 = 11.98; P < .001$). Using the Cox proportional hazards regression model, CBT was highly significant in delaying recurrence ($P = .003$).

COMMENT

This study has obvious limitations because of its preliminary nature. First, it involved a small number of patients in the evaluation of long-term effects. Second, it had a seminatualistic design because patients were initially treated with different types of antidepressant drugs, and there was no placebo-controlled withdrawal of medication. Finally,

treatment was provided by only 1 psychiatrist with extensive experience in affective disorders and CBT. The results might have been different with multiple, less experienced therapists. Nonetheless, the study provides new, important clinical insights regarding the treatment of recurrent, unipolar, major depressive disorder.

Short-term CBT after successful antidepressant drug therapy had a substantial effect on relapse rate after discontinuation of antidepressant drugs. Patients who received CBT reported a substantially lower relapse rate (25%) during the 2-year follow-up than those assigned to CM (80%). This difference was significant in terms of comparison of mean survival time and survival analysis. The high relapse rate in the CM group is in line with the findings by Frank et al.⁵ However, the patients assigned to CM in the study by Frank et al had a much shorter survival time than those in this investigation. This may be due to the very slow taper of antidepressant drugs that was endorsed by this study because this may affect outcome in mood disorders.⁴⁰ For 5 patients not included in the study, discontinuation of antidepressant drug therapy was not feasible, suggesting that the long-term outlook of recurrent depression is grim if patients are

Table 1. Sociodemographic and Clinical Characteristics of Patients Assigned to Cognitive Behavioral Treatment (CBT) of Residual Symptoms or Clinical Management (CM)*

Characteristics	CBT Group (n = 20)	CM Group (n = 20)
Age at entry, y	45.1 (10.3)	48.7 (12.1)
Sex, male/female	9/11	7/13
Marital status, married/unmarried	18/2	16/4
Social class, middle-upper/working†	16/4	16/4
Duration of illness, mo	29 (1.7)	2.6 (1.2)
No. of previous depressive episodes	3.6 (0.8)	3.5 (0.8)
Comorbidity		
Generalized anxiety disorder	6	4
Agoraphobia	3	3
Social phobia	0	1
Treatment of acute episode		
Amitriptyline hydrochloride, 150-200 mg/d	7	7
Imipramine hydrochloride, 150-200 mg/d	5	5
Desipramine hydrochloride, 150-200 mg/d	5	6
Fluoxetine, 20-40 mg/d	2	2
Sertraline hydrochloride, 150 mg/d	1	0
Benzodiazepines		
Oxazepam, 30 mg/d	2	1
Clonazepam, 1 mg/d	1	1
Prazepam, 20 mg/d	1	0
Flurazepam hydrochloride, 15 mg/d	0	1
Bromazepam, 3 mg/d	0	1
Duration of treatment, wk	15.4 (2.6)	15.8 (2.7)

*Data are given as mean (SD) and number of patients.

†According to the classification of occupations by Goldthorpe and Hope.¹⁸

left without appropriate pharmacological support or have not received psychotherapy.


The results of this investigation lend support to the findings on the importance of psychotherapy in recurrent depression by Frank et al,^{5,6} Spanier et al,⁷ and Blackburn and Moore.⁹ Results of the latter study,⁹ which had less stringent criteria for recurrent major depression, suggest the possibility that both short-term and maintenance treatment with cognitive therapy may yield better results than pharmacotherapy followed by psychotherapy. This possibility, which is intriguing also in light of sensitization hypotheses related to antidepressant use,⁴⁰⁻⁴² should be explored with future investigations.

Cognitive behavioral treatment was effective in decreasing residual symptoms of depression, replicating previous results.¹ By deferring the psychotherapeutic intervention until after pharmacotherapy, we were able to provide a less intensive course of therapy (10 sessions) than is customary (eg, 16-20 sessions) because psychotherapy could be concentrated only on the symptoms that did not abate after pharmacotherapy. The fact that most of the residual symptoms of depression are also prodromal,¹⁰ and that prodromal symptoms of relapse tend to mirror those of the initial episode,⁴³ explains the protective effect of this targeted treatment. Cognitive behavioral treatment may act on those residual symptoms of major depression that progress to become prodromal symptoms of relapse.¹² This may particularly apply to anxiety and irritability, which are prominent in the prodromal phase of depression,^{43,44} may be covered by mood disturbances but are still present in the acute phase,⁴⁵ and are again a prominent feature of its residual phase.^{1,10} Substantial comorbidity concerned with anxiety disorders

Table 2. Scores at the Clinical Interview for Depression (CID) Before and After Cognitive Behavioral Treatment (CBT) of Residual Symptoms or Clinical Management (CM)

Group	Mean (SD) CID Score		t ₁₉
	Pretreatment	Posttreatment	
CBT	30.8 (3.3)	24.0 (3.8)	10.26*
CM	29.7 (39.0)	28.1 (4.1)	0.41

*P < .001.



Proportions of depressed patients remaining in remission 2 years after cognitive behavioral therapy or clinical management.

was found in both groups. Compared with results of the previous investigation,¹⁰ CBT was not targeted to decreasing residual symptoms only. Two additional ingredients were added in view of the clinical challenge represented by a patient population with recurrent depression. One was defined as lifestyle modification. Clinical experience has suggested that recovered depressed patients are often unaware of the long-term consequences of a maladaptive lifestyle, which does not take long-term, minor life stress; interpersonal friction; excessive work (particularly in male professionals 40-50 years old); and inadequate rest into proper account. Although lifestyle modification often has been incorporated in relapse preventive strategies in depression,⁴⁶ it has been specifically addressed mainly in the clinical cardiological arena (eg, modification of type A behavior after myocardial infarction).³⁶ We postulated that the presence of subsyndromal psychiatric symptoms⁴⁷ and long-term stress exposure may cause an allostatic load, ie, fluctuating and heightened neural or endocrine responses resulting from environmental challenge.⁴⁸ Furthermore, interventions that bring the person out of negative functioning (eg, exposure treatment in panic disorder with agoraphobia²⁵) are one form of success, but facilitating progression toward restoration of the positive is another.³⁸ Ryff and Singer³⁸ suggested that the absence of well-being creates conditions of vulnerability to possible future adversities. A specific psychotherapeutic strategy that enhances well-being³⁷ was the third main ingredient of the CBT approach. It is not possible to know from our study whether these 2 additional ingredients (lifestyle modification with the ensuing sense of control and well-

being therapy) yielded specific contributions to the clinical results obtained in our investigation. In an independent, preliminary, small-scale study,³⁷ a significant advantage of well-being therapy over standard CBT strategies in decreasing residual symptoms was observed. Further research should elucidate these points.

The results of studies by Frank et al,^{5,6} Spanier et al,⁷ and Kupfer et al⁸ alerted the clinician to the need for providing maintenance therapies to patients with recurrent depression. Long-term, high-dose antidepressant drugs seemed to be the treatment of choice. This preliminary investigation, using a similar patient population, would challenge such a stance and confirm the unfavorable long-term outcome of patients not receiving pharmacotherapy or psychotherapy. Long-term maintenance drug treatment^{3,4} or psychotherapy^{4,49} may be necessary in several patients. However, our approach (CBT after pharmacotherapy) does not fall within the realm of maintenance strategies. It is a 2-stage, sequential, intensive approach that is based on the fact that treatment of depression by pharmacological means is likely to leave a substantial amount of residual symptoms in most patients.¹ Whether they reach the threshold of comorbidity, these residual symptoms hinder lasting recovery. The findings of this preliminary investigation await further large-scale, independent replications. If the effectiveness of this approach is established, the result might have important implications for the clinician and for current conceptualizations of affective disorders.⁵⁰

Accepted for publication June 3, 1998.

This work was supported in part by grants from the "Mental Health Project," Istituto Superiore di Sanità (Dr Fava), and the "Ministero dell'Università e della Ricerca Scientifica e Tecnologica" (Dr Fava and Fortunato Pesarin, PhD), Rome, Italy.

Dr Pesarin, University of Padova, Padova, Italy, provided statistical advice.

Reprints: Giovanni A. Fava, MD, Department of Psychology, University of Bologna, viale Berti Pichat 5, 40127 Bologna, Italy.

REFERENCES

- Fava GA. The concept of recovery in affective disorders. *Psychother Psychosom.* 1996;65:2-13.
- Labbate LA, Doyle ME. Recidivism in major depressive disorder. *Psychother Psychosom.* 1997;66:145-149.
- Kupfer DJ. Maintenance treatment in recurrent depression. *Br J Psychiatry.* 1992; 161:309-316.
- Fava M, Kaji J. Continuation and maintenance treatments of major depressive disorder. *Psychiatr Ann.* 1994;24:281-290.
- Frank E, Kupfer DJ, Perel JM, Cornes C, Jarrett DB, Mallinger AG, Thase ME, McEachran AB, Grochocinski VJ. Three-year outcomes for maintenance therapies in recurrent depression. *Arch Gen Psychiatry.* 1990;47:1093-1099.
- Frank E, Kupfer DJ, Wagner EF, McEachran AB, Cornes C. Efficacy of interpersonal psychotherapy as a maintenance treatment of recurrent depression: continuing factors. *Arch Gen Psychiatry.* 1991;48:1053-1059.
- Spanier C, Frank E, McEachran AB, Grochocinski VJ, Kupfer DJ. The prophylaxis of depressive episodes in recurrent depression following discontinuation of drug therapy. *Psychol Med.* 1996;26:461-475.
- Kupfer DJ, Frank E, Perel JM, Cornes C, Mallinger AG, Thase ME, McEachran AB, Grochocinski VJ. Five-year outcome for maintenance therapies in recurrent depression. *Arch Gen Psychiatry.* 1992;49:769-773.
- Blackburn IM, Moore RG. Controlled acute and follow-up trial of cognitive therapy in out-patients with recurrent depression. *Br J Psychiatry.* 1997;171:328-334.
- Fava GA, Grandi S, Zielezny M, Canestrari R, Morphy MA. Cognitive behavioral treatment of residual symptoms in primary major depressive disorder. *Am J Psychiatry.* 1994;151:1295-1299.
- Fava GA, Grandi S, Zielezny M, Rafanelli C, Canestrari R. Four-year outcome for cognitive behavioral treatment of residual symptoms in major depression. *Am J Psychiatry.* 1996;153:945-947.
- Fava GA, Kellner R. Prodromal symptoms in affective disorders. *Am J Psychiatry.* 1991;148:823-830.
- Endicott J, Spitzer RL. A diagnostic interview: the Schedule for Affective Disorders and Schizophrenia. *Arch Gen Psychiatry.* 1978;35:837-844.
- Spitzer RL, Endicott J, Robins E. *Research Diagnostic Criteria for a Selected Group of Functional Disorders.* 3rd ed. New York: Biometrics Research Division, New York State Psychiatric Institute; 1989.
- Kellner R. Improvement criteria in drug trials with neurotic patients. *Psychol Med.* 1972;2(pt 2):73-80.
- American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition.* Washington, DC: American Psychiatric Association; 1994.
- Paykel ES. Management of acute depression. In: Paykel ES, Coppen A, eds. *Psychopharmacology of Affective Disorders.* Oxford, England: Oxford University Press; 1979:235-247.
- Goldthorpe J, Hope K. *The Social Grading of Occupations.* Oxford, England: Oxford University Press; 1974.
- Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, Rush AJ, Weissman MM. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. *Arch Gen Psychiatry.* 1991;48:851-855.
- Paykel ES. The Clinical Interview for Depression. *J Affect Disord.* 1985;9:85-96.
- Fava GA, Kellner R. Staging: a neglected dimension in psychiatric classification. *Acta Psychiatr Scand.* 1993;87:225-230.
- Fava GA, Kellner R, Lisansky J, Park S, Perini GI, Zielezny M. Rating depression in normals and depressives. *J Affect Disord.* 1986;11:29-33.
- Fava GA, Savron G, Grandi S, Rafanelli C. Cognitive-behavioral management of drug-resistant major depressive disorder. *J Clin Psychiatry.* 1997;58:278-282.
- Fava GA, Grandi S, Canestrari R. Prodromal symptoms in panic disorder with agoraphobia. *Am J Psychiatry.* 1988;145:1564-1567.
- Fava GA, Grandi S, Canestrari R, Grasso P, Pesarin F. Mechanisms of change of panic attacks with exposure treatment of agoraphobia. *J Affect Disord.* 1991;22:65-71.
- Fava GA, Savron G, Rafanelli C, Grandi S, Canestrari R. Prodromal symptoms in obsessive-compulsive disorder. *Psychopathology.* 1996;29:131-134.
- Paykel ES, Ramana R, Cooper Z, Hayhurst H, Keer J, Barocka A. Residual symptoms after partial remission. *Psychol Med.* 1995;25:1171-1180.
- Fava GA, Trombini G, Barbara L, Bernardi M, Grandi S, Callegari C, Miglioli M. Depression and gastrointestinal illness. *Am J Gastroenterology.* 1985;80:195-199.
- Grandi S, Fava GA, Cunsolo A, Saviotti FM, Ranieri M, Trombini G, Gozzetti G. Rating depression and anxiety after mastectomy. *Int J Psychiatry Med.* 1990;20:163-171.
- Fava GA, Magelli C, Savron G, Conti S, Bartolucci G, Grandi S, Semprini F, Saviotti FM, Belluardo P, Magnani B. Neurocirculatory asthenia. *Acta Psychiatr Scand.* 1994;89:314-319.
- Fava GA, Savron G, Zielezny M, Grandi S, Rafanelli C, Conti S. Overcoming resistance to exposure in panic disorder with agoraphobia. *Acta Psychiatr Scand.* 1997;95:306-312.
- Pava JA, Fava M, Levenson JA. Integrating cognitive therapy and pharmacotherapy in the treatment and prophylaxis of depression: a novel approach. *Psychother Psychosom.* 1994;61:211-219.
- Beck AT, Rush AJ, Shaw BF, Emery G. *Cognitive Therapy of Depression.* New York, NY: Guilford Press; 1979.
- Beck AT, Emery G. *Anxiety Disorders and Phobias.* New York, NY: Basic Books Inc Publishers; 1985.
- Marks IM. *Fears, Phobias, and Rituals.* New York, NY: Oxford University Press Inc; 1987.
- Littman AB. Review of psychosomatic aspects of cardiovascular disease. *Psychother Psychosom.* 1993;60:149-167.
- Fava GA, Rafanelli C, Cazzaro M, Conti S, Grandi S. Well-being therapy: a novel psychotherapeutic approach for residual symptoms of affective disorders. *Psychol Med.* 1998;28:475-480.
- Ryff CD, Singer B. Psychological well-being. *Psychother Psychosom.* 1996;65:14-23.
- Lee ET. *Statistical Methods for Survival Data Analysis.* 2nd ed. New York, NY: John Wiley & Sons Inc; 1992.
- Baldessarini RJ. Risks and implications of interrupting maintenance psychotropic drug therapy. *Psychother Psychosom.* 1995;63:137-141.
- Fava GA. Do antidepressant and anti-anxiety drugs increase chronicity in affective disorders? *Psychother Psychosom.* 1994;61:125-131.
- Fava GA. Holding on: depression, sensitization by antidepressant drugs, and the prodigal experts. *Psychother Psychosom.* 1995;64:1-8.
- Fava GA, Grandi S, Canestrari R, Molnar G. Prodromal symptoms in primary major depressive disorder. *J Affect Disord.* 1990;19:149-152.
- van Praag HM. About the centrality of mood lowering in mood disorders. *Eur Neuropsychopharmacol.* 1992;2:393-404.
- Fava GA. Neurotic symptoms and major depressive illness. *Psychiatr Clin (Basel).* 1982;15:231-238.
- Thase ME. Transition and aftercare. In: Wright JH, Thase ME, Beck AT, Ludgate JW, eds. *Cognitive Therapy With Inpatients.* New York, NY: Guilford Press; 1993:414-435.
- Judd LL, Akiskal HS, Paulus MP. The role and clinical significance of subsyndromal depressive symptoms (SSD) in unipolar major depressive disorder. *J Affect Disord.* 1997;45:5-18.
- McEwen BS, Stellar E. Stress and the individual. *Arch Intern Med.* 1993;153:2093-2101.
- Thase ME, Simons AD, McGeary J, Cahalane JH, Hughes C, Harden T, Friedman E. Relapse after cognitive behavior therapy of depression: potential implications for longer course of treatment. *Am J Psychiatry.* 1992;149:1046-1052.
- Fava GA. Conceptual obstacles to research progress in affective disorders. *Psychother Psychosom.* 1997;66:283-285.